Letter in reply to 'Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper'

Affiliations

Comment

Furio Colivicchi et al. J Cardiovasc Med (Hagerstown). 2021.

. 2021 May 1;22(5):426-427.

doi: 10.2459/JCM.0000000000001164.

¹ Clinical and Rehabilitative Cardiology Unit, San Filippo Neri Hospital ASL Roma 1, Roma, Italy.

No abstract available

Comment on

Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper.
Colivicchi F, Di Fusco SA, Scicchitano P, Caldarola P, Murrone A, Valente S, Urbinati S, Roncon L, Amodeo V, Aspromonte N, Cipriani M, Domenicucci S, Francese GM, Imazio M, Scotto di Uccio F, Di Lenarda A, Gulizia MM, Gabrielli D. Colivicchi F, et al. J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):162-171. doi: 10.2459/JCM.0000000000001108. J Cardiovasc Med (Hagerstown). 2021. PMID: 32842050 Review.
Letter to the Editor: 'Updated clinical evidence and place in therapy of bempedoic acid (BA) for hypercholesterolemia: aNMCO position paper'.
Giallauria F. Giallauria F. J Cardiovasc Med (Hagerstown). 2021 May 1;22(5):425-426. doi: 10.2459/JCM.0000000000001150. J Cardiovasc Med (Hagerstown). 2021. PMID: 33399349 No abstract available.

1. Giallauria F. Letter to the editor ‘Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper’. J Cardiovasc Med (Hagerstown).
1. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41:2313–2330.
1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111–188.
1. Colivicchi F, Di Fusco SA, Scicchitano P, et al. Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper. J Cardiovasc Med (Hagerstown) 2020; doi:10.2459/JCM.0000000000001108. [Epub ahead of print]. - DOI
1. Maciejko JJ, Jamoua R, Anne P. Assessment and management of patients with hyperlipidemia referred for initiation of PCSK9 inhibitor therapy: a lipid clinic experience. Am J Cardiovasc Drugs 2019; 19:553–559.